

**OMNIBUS SOLICITATION OF THE  
NATIONAL INSTITUTES OF HEALTH,  
CENTERS FOR DISEASE CONTROL AND PREVENTION, AND  
FOOD AND DRUG ADMINISTRATION FOR**

**SMALL BUSINESS INNOVATION  
RESEARCH (SBIR)**

**AND**

**SMALL BUSINESS TECHNOLOGY  
TRANSFER (STTR)**

**GRANT APPLICATIONS**

**NIH, CDC, and FDA Program Descriptions and  
Research Topics (Revision: January 31, 2025)**

**SUBMISSION DATES**

**SEPTEMBER 5, 2024, JANUARY 5, 2025, AND  
APRIL 5, 2025**

**National Institutes of Health (SBIR and STTR)  
Centers for Disease Control and Prevention (SBIR)  
Food and Drug Administration (SBIR)**

Notices of Funding Opportunities, Application Instructions, and Appendices are contained in separate files. Follow the links below to view these documents.

---

## NOTICES OF FUNDING OPPORTUNITIES

**REMINDER: ALL APPLICATIONS MUST BE SUBMITTED IN RESPONSE TO A NOTICE OF FUNDING OPPORTUNITY THROUGH GRANTS.GOV**

[PHS 2024-02 OMNIBUS SOLICITATION OF THE NIH, CDC, AND FDA FOR SMALL BUSINESS INNOVATION RESEARCH GRANT APPLICATIONS \(PARENT SBIR \[R43/R44\] CLINICAL TRIAL NOT ALLOWED\)](#)

[PHS 2024-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS TECHNOLOGY TRANSFER GRANT APPLICATIONS \(PARENT STTR \[R41/R42\] CLINICAL TRIAL NOT ALLOWED\)](#)

[PHS 2024-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS INNOVATION RESEARCH GRANT APPLICATIONS \(PARENT SBIR \[R43/R44\] CLINICAL TRIAL REQUIRED\)](#)

[PHS 2024-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS TECHNOLOGY TRANSFER GRANT APPLICATIONS \(PARENT STTR \[R41/R42\] CLINICAL TRIAL REQUIRED\)](#)

[ADDITIONAL SPECIAL ANNOUNCEMENTS FOR SMALL BUSINESS RESEARCH OPPORTUNITIES](#)

---

## APPLICATION INSTRUCTIONS

[SF424 \(R&R\) APPLICATION INSTRUCTIONS AND ELECTRONIC SUBMISSION INFORMATION](#)

## TABLE OF CONTENTS

---

<b>NIH, CDC, AND FDA PROGRAM DESCRIPTIONS AND RESEARCH TOPICS</b>	
<b>OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, AND FOOD AND DRUG ADMINISTRATION</b>	<b>. 1</b>
<b>TABLE OF CONTENTS</b>	<b>3</b>
<b>PROGRAM DESCRIPTIONS AND RESEARCH GRANT TOPICS</b>	<b>5</b>
<b>NATIONAL INSTITUTES OF HEALTH (NIH)</b>	<b>5</b>
NATIONAL INSTITUTE ON AGING (NIA)	6
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)	8
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)	10
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS)	15
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB)	16
NATIONAL CANCER INSTITUTE (NCI)	17
<i>EUNICE KENNEDY SHRIVER</i> NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)	20
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)	23
NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD)	25
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR)	26
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK)	27
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS)	30
NATIONAL EYE INSTITUTE (NEI)	32
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS)	34
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI)	36
NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI)	39
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH)	40
NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES (NIMHD)	43
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS)	44
NATIONAL INSTITUTE OF NURSING RESEARCH (NINR)	45
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)	46
NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH)	48
NATIONAL LIBRARY OF MEDICINE (NLM)	49

DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI), OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP)	50
OFFICE OF RESEARCH ON WOMEN'S HEALTH (ORWH)	52
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)	53
FOOD AND DRUG ADMINISTRATION (FDA)	59

---

## PROGRAM DESCRIPTIONS AND RESEARCH GRANT TOPICS

Grant applications will be accepted and considered in any area within the mission of the awarding components (i.e., Institutes and Centers (ICs)) identified in this solicitation. Information about the HHS SBIR and STTR programs for applicants and awardees, including resources and programs available to HHS SBIR and STTR awardees, can be found at <https://seed.nih.gov/>.

Applicants are strongly encouraged to subscribe to the [NIH Guide for Grants and Contracts LISTSERV](#) or query program administrators periodically via email to learn of new or emerging scientific interests of the NIH, CDC, and FDA awarding components.

You may also subscribe to the [SBIR-STTR LISTSERV](#) to get timely information about the NIH SBIR and STTR Programs.

Additional information on each of the awarding components (ICs) and their research interests is available electronically on the home pages shown throughout the “Research Topics” section of the solicitation.

---

### NATIONAL INSTITUTES OF HEALTH (NIH)

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.

Information about the NIH SBIR and STTR programs for applicants and awardees, including resources and programs available to NIH SBIR and STTR awardees, can be found at <https://seed.nih.gov/>.

To carry out these responsibilities, the NIH is organized into awarding components (Institutes and Centers). Those components that have an extramural element, that is, those that provide funds for research and research training activities in organizations external to the NIH, are shown below. The NIH makes every effort to finance worthy applications, including the co-funding of such applications by one or more awarding components having relevance in the projects.

Total funding support (direct costs, indirect costs, fees) normally may not exceed \$314,363 for Phase I awards and \$2,095,748 for the duration of the Phase II awards. However, this amount is subject to change and the most current information can be found on the [NIH SEED website](#). Awards exceeding these amounts may be made at the discretion of an Institute or Center for applications within one of the [SBA-Approved Waiver Topics](#). Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Funding levels for projects are determined through the combined interaction among peer review, grants management, program, budget, and other Institute and/or Center staff. These levels are based on allowable costs that are consistent with the principles of sound cost management and in consideration of Institute or Center priorities, constraints on the growth of average grant costs, and the availability of funds.

Before considering and/or preparing an application to the SBIR and STTR programs, all applicants are **strongly encouraged** to review the agencies’ and NIH Institutes’ and Centers’ websites and to contact the SBIR and STTR program coordinators listed below. The Fogarty International Center, which provides support only for conferences, postdoctoral fellowships for research in the United States and abroad, and senior scientist exchanges between the United States and other countries, does not participate in the SBIR and STTR program.

#### **Contact Information**

Questions of a general nature about the HHS SBIR and STTR program may be directed to:  
SEED (Small business Education and Entrepreneurial Development)

Email: [SEEDinfo@nih.gov](mailto:SEEDinfo@nih.gov)

For Agency, Institute and Center Scientific/Research (Program) and Financial/Grants Management contacts, please see the [contact page](#).

## NATIONAL INSTITUTE ON AGING (NIA)

<https://www.nia.nih.gov/>

For more information on the NIA SBIR and STTR programs:

<https://www.nia.nih.gov/research/sbir>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#), unless the application fits an SBA-approved NIA waiver topic. For topics listed in the [SBA-Approved Waiver Topics](#), the NIA generally will not fund Phase I applications to the Omnibus greater than \$400,000 total costs or project periods greater than 2 years; or Phase II applications greater than \$2,250,000 total costs or project periods greater than 3 years.

However, if your application is AD/ADRD focused, you may come in at \$500,000 for Phase I and \$2,500,000 for Phase II (total costs). For budgetary, administrative, or programmatic reasons, the NIA may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIA welcomes submission of Phase IIB Competing Renewal grant applications from Phase II SBIR/STTR awardees to continue the process of developing a wide range of aging-focused products, including digital- mobile/cyber-health technology, pharmaceutical compounds, and medical devices. The Phase IIB Competing Renewal award is intended to allow small businesses the opportunity to realize further progress in commercialization, including stimulating interest in and investment by third parties. NIA will generally not fund Phase IIBs greater than \$3M total costs.

Prospective Phase IIB Competing Renewal applicants are strongly encouraged to contact NIA's SBIR-STTR program contact prior to consideration and preparation of a Phase IIB application and well in advance of the SBIR-STTR submission due dates.

NIA also welcomes the submission of CRP applications to the 2 CRP NOFOs (and subsequent reissued NOFOs):

- SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development - Clinical Trial Not Allowed ([PAR-23-219](#))
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development - Clinical Trial Required ([PAR-23-220](#))

### **Contact Information**

For more information on research topics and questions about potential NIA SBIR/STTR grant applications and NIA's participation in the Phase IIB or CRP programs, please contact:

#### **Program Contacts, NIA Small Business R & D Programs:**

Michael-David ("M-D") A.R.R.Kerns, M.M., M.S., Ph.D.

National Institute on Aging (NIA)

Email: [niasmallbusiness@mail.nih.gov](mailto:niasmallbusiness@mail.nih.gov)

Bio: <https://www.nia.nih.gov/about/staff/kerns-michael-david>

[Rajesh Kumar, Ph.D.](#)

National Institute on Aging (NIA)

Email: [niasmallbusiness@mail.nih.gov](mailto:niasmallbusiness@mail.nih.gov)

If there are specific questions pertaining to the interests or activities of the NIA scientific divisions, contact:

**Division of Aging Biology:**

Leonid Tsap, Ph.D.

National Institute on Aging (NIA)

Email: [Leonid.Tsap@nih.gov](mailto:Leonid.Tsap@nih.gov)

Bio: <https://www.nia.nih.gov/about/staff/tsap-leonid>

**Division of Behavioral and Social Research:**

Dinesh John, Ph.D.

National Institute on Aging (NIA)

Email: [dinesh.john@nih.gov](mailto:dinesh.john@nih.gov)

Bio: <https://www.nia.nih.gov/about/staff/john-dinesh>

**Division of Geriatrics and Clinical Gerontology:**

Lyndon Joseph, Ph.D.

National Institute on Aging (NIA)

Telephone: 301-496-6761

Email: [lyndon.joseph@nih.gov](mailto:lyndon.joseph@nih.gov)

Bio: <https://www.nia.nih.gov/about/staff/joseph-lyndon>

**Division of Neuroscience:**

Zane Martin, Ph.D.

National Institute on Aging (NIA)

Email: [zane.martin@nih.gov](mailto:zane.martin@nih.gov)

Bio: <https://www.nia.nih.gov/about/staff/martin-jones-zane>

## NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)

<http://www.niaaa.nih.gov>

For more information on the NIAAA SBIR and STTR programs:

<https://www.niaaa.nih.gov/research/niaaa-sbir>

### **Budget Guidance**

NIAAA will make awards compliant with all statutory guidelines as outlined above. Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the Small Business Administration (SBA), which can be found on the [NIH SEED website](#). With the exception of the topics indicated therein, NIAAA will generally not fund Phase I applications to the Omnibus greater than \$385K or Phase II awards over \$3M total costs even if topics are listed under the [SBA-Approved Waiver Topics](#). Applicants considering a requested budget greater than the standard limits are strongly encouraged to contact the [NIAAA SBIR/STTR Program Director](#) before submitting an application. For budgetary, administrative, or programmatic reasons, NIAAA may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIAAA will accept SBIR/STTR Phase IIB Competing Renewal grant applications from Phase II SBIR/STTR awardees to continue the process of developing products that require approval of a Federal regulatory agency (e.g., FDA, FCC). Such products include, but are not limited to, medical implants, drugs, vaccines, biologicals, and new treatment or diagnostic tools that require FDA approval. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. To be eligible for Phase IIB consideration, the project must retain high significance in the light of current market conditions.

Prospective applicants are strongly encouraged to contact NIH staff well in advance of submitting a Phase IIB Competing Renewal application by submitting to [niaaasbirsttr@mail.nih.gov](mailto:niaaasbirsttr@mail.nih.gov) a letter of intent that includes the following information:

- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Grant number and title
- Progress of the Phase II award
- Goals and justification for the Phase IIB request

It is expected that only a portion of NIAAA SBIR/STTR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.

NIAAA will accept submission of CRP applications to the following NOFOs (and reissues):

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development - Clinical Trial Not Allowed ([PAR-23-219](#))

SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development - Clinical Trial Required ([PAR-23-220](#))



**Contact Information**

Megan Ryan, M.B.A.  
NIAAA SBIR/STTR Program Director  
National Institute on Alcohol Abuse and Alcoholism  
6700B Rockledge Dr.  
Rockville, MD 20852-1705  
Phone: 301-827-6166  
Email: [mryan1@nih.gov](mailto:mryan1@nih.gov)

For general inquiries: [NIAAASBIRSTTR@mail.nih.gov](mailto:NIAAASBIRSTTR@mail.nih.gov)

For administrative and business management questions, contact:

Jeff Thurston  
SBIR/STTR Grants Management Lead  
National Institute on Alcohol Abuse and Alcoholism  
Phone: 301-443-9801  
Email: [jeffrey.thurston@nih.gov](mailto:jeffrey.thurston@nih.gov)

## NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

<http://www.niaid.nih.gov>

For more information on the NIAID SBIR and STTR programs:

<https://www.niaid.nih.gov/grants-contracts/small-businesses>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fee) normally may not exceed the dollar amounts specified by the SBA, which can be found on the [NIH SEED website](#). Budget requests at or near these hard caps should be well justified. Phase II/IIB applicants should note that NIAID **will not** generally allow awards (of any duration) that exceed \$1,000,000 total costs per year.

NIH has received a waiver from SBA, as authorized by statute, to exceed total award amount hard caps for specific topics. The current list of approved NIAID topics is included in the [SBA-Approved Waiver Topics](#). Topics that align with NIAID's priority research areas are listed for each Division; any listed NIAID topic is sufficient to consider budget requests that exceed the hard caps. Budget requests exceeding the hard caps must be very well justified in the "Budget Justification" attachment to the Research and Related Budget form and be clearly consistent with the scope of the proposal.

For proposals that address an approved topic, NIAID will allow Phase I applications with budgets of up to \$300,000 total costs per year for up to 2 years; and Phase II or Phase IIB applications with budgets of up to \$1,000,000 total costs per year for up to 3 years. Requests for these budget levels must be very well-justified. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

NIAID staff cannot provide prior approval to exceed hard caps. Compliance with a pre-approved topic will be confirmed at time of award by the applicant's Grants Management Specialist and Program Officer.

NIAID will consider well justified Technical and Business Assistance (TABAs) costs up to the limits specified on the [NIH SEED Website](#). These costs can be requested *in addition* to the Phase I and II limits indicated above.

NIAID will generally not make SBIR or STTR awards with budgets that exceed these guidelines. For budgetary, administrative, or programmatic reasons, NIAID may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIAID welcomes Phase IIB Competing Renewal Applications (**SBIR only**) for Phase II grants and contracts via the Omnibus Solicitation for SBIR Grant Applications, and as indicated by other NIAID Notices of Funding Opportunities (NOFOs). Standard NIAID Phase II funding policy applies unless otherwise stated in the NOFO. STTR Phase II awardees may apply but must switch programs to SBIR. Non-NIAID Phase II awardees must contact NIAID prior to submission to confirm programmatic interest.

NIAID welcomes CRP applications from eligible NIAID Phase II/IIB awardees through [PAR-20-129](#) (and subsequent reissued NOFOs) Please review this Notice of Funding Opportunity for details.

## **Contact Information**

For more information on NIAID's SBIR/STTR research topics, program policy or to identify NIAID Subject Matter Experts for a specific topic, please contact:

Dr. Natalia Kruchinin  
SBIR/STTR Program  
Coordinator Division of  
Extramural Activities  
National Institute of Allergy and Infectious  
Diseases Phone: 240-669-2919  
Email: [kruchininn@niaid.nih.gov](mailto:kruchininn@niaid.nih.gov)

### **Division of AIDS**

Director: Dr. Carl Dieffenbach  
Telephone: 301-496-0545  
Email: [CDieffenba@niaid.nih.gov](mailto:CDieffenba@niaid.nih.gov)

Division Small Business Representative:

Dr. Brigitte Sanders  
Telephone: 240-627-3209  
E-mail: [sandersbe@niaid.nih.gov](mailto:sandersbe@niaid.nih.gov)

Vaccine Research Program (VRP)

Director: Dr. James Lane (acting)  
Telephone: 301-435-3727  
Email: [laneji@mail.nih.gov](mailto:laneji@mail.nih.gov)

Vaccine Clinical Research Branch (VCRB)

Contact: Dr. Patricia D'Souza  
Telephone: 240-627-3037  
Email: [pdsouza@niaid.nih.gov](mailto:pdsouza@niaid.nih.gov)

Preclinical Research and Development Branch (PRDB)

Contact: Dr. Anjali Singh  
Telephone: 240-627-3030  
Email: [anjalisingh@niaid.nih.gov](mailto:anjalisingh@niaid.nih.gov)

Vaccine Translational Research Branch (VTRB)

Contact: Dr. Michael Pensiero  
Telephone: 301-435-3749  
Email: [mpensiero@niaid.nih.gov](mailto:mpensiero@niaid.nih.gov)

Basic Sciences Program (BSP)

Director: Dr. Diana Finzi  
Telephone: 301-451-2598  
Email: [Dfinzi@niaid.nih.gov](mailto:Dfinzi@niaid.nih.gov)

Pathogenesis and Basic Research Branch (PBRB)

Contact: Dr. Karl Salzwedel  
Telephone: 301-496-5332  
Email: [salzwedelkd@niaid.nih.gov](mailto:salzwedelkd@niaid.nih.gov)

Targeted Interventions Branch (TIB)  
Contact: Dr. Brigitte Sanders  
Telephone: 240-627-3209  
E-mail: [sandersbe@niaid.nih.gov](mailto:sandersbe@niaid.nih.gov)

Epidemiology Branch (EB)  
Contact: Lori Zimand  
Telephone: 240-627 3212  
Email: [lzimand@niaid.nih.gov](mailto:lzimand@niaid.nih.gov)

Therapeutics Research Program (TRP)  
Director: Dr. Peter Kim  
Telephone: 301-451-2761  
Email: [peter.kim2@nih.gov](mailto:peter.kim2@nih.gov)

Drug Development and Preclinical Research Branch (DDPRB)  
Contact: Roger Ptak  
Telephone: 301-761-7424  
Email: [roger.ptak@nih.gov](mailto:roger.ptak@nih.gov)

Complications and Co-infections Research Branch (CCRB)  
Contact: Dr. Beverly Alston  
Telephone: 301-435-3773  
Email: [balston@niaid.nih.gov](mailto:balston@niaid.nih.gov)

HIV Research Branch (HIVRB)  
Contact: Tia Morton, RN  
Telephone: 240-627-3073  
Email: [frazierti@niaid.nih.gov](mailto:frazierti@niaid.nih.gov)

TB Clinical Research Branch (TCRB)  
Contact: Dr. Andrew Vernon  
Telephone: 301-761-5130  
Email: [andy.vernon@nih.gov](mailto:andy.vernon@nih.gov)

Laboratory and Clinical Sciences Branch (LCSB)  
Contact: Dr. Fatima Jones  
Telephone: 240-550-7863  
Email: [maria.jones@nih.gov](mailto:maria.jones@nih.gov)

Prevention Sciences Program (PSP)  
Director: Dr. Sheryl Zwierski  
Telephone: 301-402-4032  
Email: [szwerski@niaid.nih.gov](mailto:szwerski@niaid.nih.gov)

Clinical Prevention Research Branch (CPRB)  
Contact: Dr. Lydia Soto-Torres  
Telephone: 240-292-4807  
Email: [lsoto-torres@niaid.nih.gov](mailto:lsoto-torres@niaid.nih.gov)

Preclinical Microbicide & Prevention Research Branch (PMPRB)  
Contact: Dr. James Cummins  
Telephone: 240-292-4800  
Email: [cumminsje@niaid.nih.gov](mailto:cumminsje@niaid.nih.gov)

Maternal, Adolescent and Pediatric Research Branch (MAPRB)  
Contact: Judi Miller  
Telephone: 240-292-4801  
Email: [jmillera@niaid.nih.gov](mailto:jmillera@niaid.nih.gov)

**Division of Allergy, Immunology and Transplantation (DAIT)**

Director: Daniel Rotrosen, M.D.  
Telephone: 301-496-1886  
Email: [drotrosen@niaid.nih.gov](mailto:drotrosen@niaid.nih.gov)

Division Small Business Representative:  
Dr. Michael Minnicozzi  
Telephone: 240-627-3532  
E-mail: [minnicozzim@niaid.nih.gov](mailto:minnicozzim@niaid.nih.gov)

Allergy, Asthma, and Airway Biology Branch  
Chief: Alkis Togias, M.D.  
Telephone: 301-496-8973  
Email: [togiasa@niaid.nih.gov](mailto:togiasa@niaid.nih.gov)

Basic Immunology Branch  
Chief: Dr. Alison Deckhut-Augustine  
Telephone: 301-496-7551, Fax: 301-480-2381  
Email: [augustine@niaid.nih.gov](mailto:augustine@niaid.nih.gov)

Autoimmunity and Mucosal Immunology Branch  
Chief: Dr. Ellen Goldmuntz  
Telephone: 240-627 3502  
Fax: 301-480-1450  
Email: [egoldmuntz@niaid.nih.gov](mailto:egoldmuntz@niaid.nih.gov)

Transplantation Branch  
Chief: To be announced  
Telephone: TBD  
Email: TBD

Radiation and Nuclear Countermeasures Program  
Director: Andrea L. DiCarlo, PhD  
Telephone: 240-627-3492  
Email: [cohen@niaid.nih.gov](mailto:cohen@niaid.nih.gov)

RNCP SBIR Contact:  
Carmen I. Rios, PhD  
Telephone: 240-627-3553  
Email: [carmen.rios@nih.gov](mailto:carmen.rios@nih.gov)

## **Division of Microbiology and Infectious Diseases (DMID)**

Director: Emily Erbelding, M.D., M.P.H.

Telephone: 301-435-3384

Email: [emily.erbelding@nih.gov](mailto:emily.erbelding@nih.gov)

Division Small Business Representative:

Dr. Barbara Mulach

Telephone: 240-627-3322

Email: [bmulach@niaid.nih.gov](mailto:bmulach@niaid.nih.gov)

Division Small Business Representative:

Dr. Alyssa Werner

Telephone: 301-761-7525

Email: [alyssa.werner@nih.gov](mailto:alyssa.werner@nih.gov)

Office of Genomics and Advanced Technologies (OGAT)

Contact: Dr. Inka Sastalla

Telephone: 301-761-6431

Email: [sastallai@mail.nih.gov](mailto:sastallai@mail.nih.gov)

Virology Branch (VB)

Contact: Dr. Julie Dyll

Telephone: 301-631-7296

Email: [Julie.dyll@niaid.nih.gov](mailto:Julie.dyll@niaid.nih.gov)

Bacteriology and Mycology Branch (BMB)

Contact: Dr. Alec Ritchie

Telephone: 240-627-3356

Email: [aritchie@niaid.nih.gov](mailto:aritchie@niaid.nih.gov)

Enteric and Sexually Transmitted Infections Branch (ESTIB)

Contact: Dr. Tom Hiltke

Telephone: 240-627-3275

Email: [thiltke@niaid.nih.gov](mailto:thiltke@niaid.nih.gov)

Parasitology and International Programs Branch (PIPB)

Contact: Dr. Annie Mo

Telephone: 240-627-3320

Email: [moa@niaid.nih.gov](mailto:moa@niaid.nih.gov)

Respiratory Diseases Branch (RDB)

Contact: Dr. Xin-Xing Gu

Telephone: 240-627-3265

Email: [guxx@niaid.nih.gov](mailto:guxx@niaid.nih.gov)

Office of Biodefense Research and Surety (OBRS)

Biodefense Research Countermeasures Branch (BRCB)

Contact: Dr. Dave Yeung

Telephone: 301-761-7237

Email: [dy70v@nih.gov](mailto:dy70v@nih.gov)

# NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS)

<http://www.niams.nih.gov>

For more information on the NIAMS SBIR and STTR programs:

<https://www.niams.nih.gov/grants-funding/funding-opportunities/small-business-grants>

## **Budget Guidance**

For budgetary, administrative, or programmatic reasons, NIAMS may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#).

For topics listed in the [SBA-Approved Waiver Topics](#), NIAMS does not apply these topics to the Omnibus Program Announcements. NIAMS only applies the waiver topics to special Notices of Funding Opportunities that specifically allow higher budgets than those in the Omnibus Program Announcements. When the waiver topics are applied, NIAMS generally will not fund Phase I applications greater than \$350,000 total costs or project periods greater than 2 years; or Phase II applications greater than \$2,300,000 total costs or project periods greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

NIAMS provides Technical and Business Assistance (TABAs) Funding. Small Businesses may request up to \$6,500 per year for a Phase I and up to \$50,000 per Phase II project (across all years) to support subcontracts or consultants above the budget cap. Small businesses should include this budget request as part of the application and provide a detailed budget justification.

## **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIAMS does not accept Phase IIB renewal applications. NIAMS participates in the CRP program and sets its own budget limits for the CRP applications in the program announcements. NIAMS does not support clinical trials through the CRP program.

## **Contact Information**

For general SBIR/STTR program information, contact:

Dr. Xibin Wang, NIAMS SBIR/STTR Coordinator

Telephone: 301-451-3884

Fax: 301-480-1284

Email: [wangx1@mail.nih.gov](mailto:wangx1@mail.nih.gov)

For administrative and business management questions, contact:

Ms. Victoria Matthews

Telephone: 301-594-3968

Fax: 301-480-5450

Email: [victoria.matthews@nih.gov](mailto:victoria.matthews@nih.gov)

## NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB)

<http://www.nibib.nih.gov>

For more information on the NIBIB SBIR and STTR programs:

<https://www.nibib.nih.gov/programs/small-business-programs>

### **Budget Guidance**

Normally, total funding support (direct costs, indirect costs, fees) may **not** exceed the amounts defined by the Small Business Administration (SBA), which can be found on the [NIH SEED website](#).

Applicants considering a requested budget greater than the current SBA guidelines should ensure that the project falls within a topic listed in the [SBA-Approved Waiver Topics](#).

Generally, NIBIB will **not** support Phase I (R41/R43) project periods greater than 1 year, or Phase II (R42/R44) project periods greater than 2 years.

For budgetary, administrative, or programmatic reasons, NIBIB may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIBIB does **not** accept Phase IIB renewal application through the Omnibus Solicitations.

NIBIB participates in the [Commercialization Readiness Pilot \(CRP\)](#) program for **Phase II applications only**.

### **Contact Information**

For additional information on research topics, contact:

Dr. Kari Ashmont

National Institute of Biomedical Imaging and Bioengineering

Telephone: 301-451-4772, Fax: 301-480-1614

Email: [NIBIB-SBIR@mail.nih.gov](mailto:NIBIB-SBIR@mail.nih.gov)

For administrative and business management questions, contact:

Mr. James Huff

National Institute of Biomedical Imaging and Bioengineering

Telephone: 301-451-4786, Fax: 301-451-5735

Email: [huffj@mail.nih.gov](mailto:huffj@mail.nih.gov)



## NATIONAL CANCER INSTITUTE (NCI)

<https://www.cancer.gov/>

For more information on the NCI SBIR and STTR programs:

<http://sbir.cancer.gov>

### **Budget Guidance**

For budgetary, administrative, or programmatic reasons, NCI may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). However, for certain research topics, the U.S. Small Business Administration has approved a list of [SBA-Approved Waiver Topics](#) for which the NCI generally will fund Phase I applications with higher budgets up to \$400,000 total costs combined over all years, and project periods up to 2 years; similarly, for certain research topics, NCI will consider Phase II applications with higher budgets up to \$2,250,000 total costs combined over all years, and project periods up to 3 years.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

The National Cancer Institute (NCI) welcomes CRP applications from companies that have active or completed NCI SBIR (Phase II and Phase IIB) or STTR (Phase II) awards ([PAR-20-128](#)).

Please note that NCI will provide funding support up to a maximum of \$250,000 in total costs (direct costs, indirect costs, and fee). Potential applicants are strongly encouraged to contact NCI SBIR Program staff to discuss prior to submission the CRP activities for which support will be requested. The NCI may decline funding of any application for reasons of program balance or budget. NCI does not participate in the SBIR/STTR Commercialization Readiness Pilot Program Technical Assistance and Late-Stage Development (SB1) NOFOs (PAR-20-129 or PAR-20-130). For SBIR/STTR Phase II awardees in need of additional assistance for late-stage development and/or clinical trials, the NCI recommends its SBIR Phase IIB program.

### **Phase IIB**

The NCI does not accept applications for Phase IIB SBIR competing renewal awards through this Omnibus Solicitation. However, the NCI offers Phase IIB opportunities in the form of the NCI SBIR Phase IIB Bridge Award, which is announced via a separate funding solicitation: <https://sbir.cancer.gov/bridge>. Please note that NCI will provide funding support up to a maximum of \$4,500,000 in total costs (direct costs, indirect costs, and fee). The NCI Phase IIB Bridge Award is designed to support the next stage of development for cancer-related technologies previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this award is to address the funding gap known as the "Valley of Death" between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between federally funded SBIR Phase II awardees and third-party investors and/or strategic partners. Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).

To ensure that you will be notified upon the release of the NCI SBIR Phase IIB Bridge Award solicitation, please sign up for the NCI SBIR mailing list: <https://bit.ly/NciSbirEmailSignUp>. If you have any questions regarding the NCI SBIR Phase IIB Bridge Award, please contact your Phase II program director.

## **Contact Information**

**For additional information about the NCI SBIR/STTR programs, please contact the NCI SBIR Development Center:**

9609 Medical Center Drive  
Rockville, MD 20850  
Website: <http://sbir.cancer.gov>  
Email: [NCIsbir@mail.nih.gov](mailto:NCIsbir@mail.nih.gov)  
Phone: 240-276-5300

**For additional information on research topics, please contact a Program Officer with the relevant area of expertise:**

Michael Weingarten, MA  
Director, NCI SBIR Development Center  
Email: [weingartenm@mail.nih.gov](mailto:weingartenm@mail.nih.gov)

Gregory Evans, PhD  
Program Director and Team Leader  
Email: [evansgl@mail.nih.gov](mailto:evansgl@mail.nih.gov)  
*Areas of Expertise: Therapeutics (Immunotherapy, Gene Therapy), Cancer Imaging, Cancer Control, Tools for Cancer Biology Research, and Digital Health*

Jonathan Franca-Koh PhD, MBA  
Program Director and Team Leader  
Email: [jonathan.franca-koh@nih.gov](mailto:jonathan.franca-koh@nih.gov)  
*Areas of Expertise: Cancer Biology, Biologics, Small Molecules, and Cell-Based Therapies*

Monique Pond, PhD  
Program Director and Team Leader  
Email: [monique.pond@nih.gov](mailto:monique.pond@nih.gov)  
*Areas of Expertise: Biologics, Small Molecules, Therapeutic Devices, Digital Health, Regulatory Resources*

Patricia Weber, DrPH  
Program Director  
Email: [weberpa@mail.nih.gov](mailto:weberpa@mail.nih.gov)  
*Areas of Expertise: Digital Health and Therapeutics (Small Molecules, Biologics, Immunotherapy)*

Xing-Jian Lou, PhD  
Program Director  
Email: [loux@mail.nih.gov](mailto:loux@mail.nih.gov)  
*Areas of Expertise: In Vitro Diagnostics and Therapeutics (Gene Therapy, Biologics, Small Molecules)*

Ming Zhao, PhD  
Program Director  
Email: [zhaoming3@mail.nih.gov](mailto:zhaoming3@mail.nih.gov)  
*Areas of Expertise: In Vitro Diagnostics, Cancer Stem Cells, Molecular Imaging, Bioinformatics, Therapeutics (Small Molecules, Biologics, Immunotherapy), and Cancer Control (Community-Based Participatory Research)*

William Bozza, PhD  
Program Director  
Email: [william.bozza@nih.gov](mailto:william.bozza@nih.gov)  
*Areas of Expertise: Biologics, Protein Therapeutics, Regulatory (CMC)*

Sarra Djemil, PhD  
Program Director  
Email: [sarra.djemil@nih.gov](mailto:sarra.djemil@nih.gov)  
*Areas of Expertise: Therapeutics, Digital Health, Mentoring*

Saroj Regmi, PhD  
Program Director  
Email: [saroj.regmi@nih.gov](mailto:saroj.regmi@nih.gov)  
*Areas of Expertise: Therapeutics, Diagnostics, Imaging, Digital Health, Investor Initiatives, Small Business Transition Grant, I-Corps*

Swamy Tripurani, PhD  
Program Director  
Email: [swamy.tripurani@nih.gov](mailto:swamy.tripurani@nih.gov)  
*Areas of Expertise: Therapeutics, Biologics, Small Molecules, Diagnostics, Devices, and Regulatory (CMC and Nonclinical)*

Melissa Li, PhD  
Program Director  
Email: [melissa.li@nih.gov](mailto:melissa.li@nih.gov)  
*Areas of Expertise: Biologics, Small Molecules, Digital Health*

Linda Zane, PhD  
Program Director  
Email: [linda.zane@nih.gov](mailto:linda.zane@nih.gov)  
*Areas of Expertise: Therapeutics, Diagnostics, Research Tools*

## **EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)**

<http://www.nichd.nih.gov>

**For more information on the NICHD SBIR and STTR programs:**

[https://www.nichd.nih.gov/grants-contracts/SBIR\\_STTR](https://www.nichd.nih.gov/grants-contracts/SBIR_STTR)

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). It is strongly encouraged to contact program staff prior to applying.

The NICHD received a budgetary guideline waiver from the Small Business Administration for applications relating to a limited list of scientific topics in [SBA-Approved Waiver Topics](#). For these the NICHD will accept applications up to \$400K total costs for Phase I and \$2.25M for Phase II. Applicants should propose a budget that is reasonable and appropriate for completion of the research project and requests for these budget levels must be very well justified. Applicants are encouraged to contact the listed NICHD Branch Contact Program Officer for scientific-related questions about a project's eligibility for a budgetary waiver.

For general budgetary questions, applicants should contact NICHD's SBIR/STTR Grants Management Coordinator. **The NICHD may decrease the budget or length of an award or decide not to fund an application for budgetary, administrative, or programmatic reasons.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

The NICHD accepts Phase IIB SBIR Competing Renewal applications to support additional R&D necessary for approval of a federal regulatory agency (e.g., FDA, FCC). Such products may include medical implants, pediatric devices, drugs, vaccines, and new treatment or diagnostic tools. Applicants who received NICHD SBIR Phase II support and who are currently Phase II awardees are eligible. If the project meets the criteria for a budgetary waiver (see [SBA-Approved Waiver Topics](#)), the Phase IIB should not exceed \$3M total costs for three years. The amount of award may vary year to year depending on the research proposed. **Funding priority will be given to those small business concerns that show the ability to develop innovative products and demonstrate growth towards independence from the SBIR/STTR programs.**

**Prospective applicants are strongly encouraged to contact NICHD program staff well in advance of submitting a Phase IIB Competing Renewal application.**

### **Contact Information**

#### **Child Development and Behavior Branch**

NICHD CDBB Small Business (SB) Program Director

Phone: 301-435-6855 OR 301-435-3602

Email: [NICHDCDBB-SB-Program@mail.nih.gov](mailto:NICHDCDBB-SB-Program@mail.nih.gov)

#### **Contraception Research Branch**

Steven C. Kaufman, MD, MS

Phone: 301-435-6989

Email: [kaufmans@exchange.nih.gov](mailto:kaufmans@exchange.nih.gov)

**Developmental Biology and Congenital Anomalies Branch**

Mahua Mukhopadhyay, PhD

Phone: 301-435-6886

Email: [mukhopam@mail.nih.gov](mailto:mukhopam@mail.nih.gov)

**Fertility and Infertility Branch**

Clara Cheng, PhD

Phone: 301-435-6992

Email: [clara.cheng@nih.gov](mailto:clara.cheng@nih.gov)

**Gynecologic Health and Disease Branch**

Candace M. Tingen, PhD

Phone: 301-435-6971

Email: [candace.tingen@nih.gov](mailto:candace.tingen@nih.gov)

**Intellectual and Developmental Disease Branch**

Sujata Bardhan, PhD

Phone: 301-435-0471

Email: [sujata.bardhan@nih.gov](mailto:sujata.bardhan@nih.gov)

**Maternal and Pediatric Infection Disease Branch**

Sai Majji, PhD

Phone: 301-402-8048

Email: [sai.majji@nih.gov](mailto:sai.majji@nih.gov)

**Obstetric and Pediatric Pharmacology and Therapeutics Branch**

Antonello Pileggi, MD, PhD, MSCTI

Phone: 301-402-5019

Email: [pileggia@nih.gov](mailto:pileggia@nih.gov)

**Pediatric Growth and Nutrition Branch**

Andrew A. Bremer, MD, PhD

Phone: 301-402-7886

Email: [andrew.bremer@nih.gov](mailto:andrew.bremer@nih.gov)

**Pediatric Trauma and Critical Illness Branch**

Tessie October, MD, MPH

Phone: 301-827-6757

Email: [tessie.october@nih.gov](mailto:tessie.october@nih.gov)

**Population Dynamics Branch**

Ronna Popkin, PhD

Phone: 301-827-5121

Email: [ronna.popkin@nih.gov](mailto:ronna.popkin@nih.gov)

**Pregnancy and Perinatology Branch**

Diane Gumina, PhD

Phone: 301-827-7304

Email: [diane.gumina@nih.gov](mailto:diane.gumina@nih.gov)

**National Center for Medical Rehabilitation Research**

Toyin Ajisafe, PhD

Phone: 301-827-9242

Email: [toyin.ajisafe@nih.gov](mailto:toyin.ajisafe@nih.gov)

For additional SBIR/STTR program administrative information and research topics contact:

Toyin Ajisafe, PhD

Phone: 301-827-9242

Email: [toyin.ajisafe@nih.gov](mailto:toyin.ajisafe@nih.gov)

For additional financial/business management questions contact:

Mindy Bixby, Grants Management Specialist

Phone: 301-402-3204

Email: [mindy.bixby@nih.gov](mailto:mindy.bixby@nih.gov)

## NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)

<https://nida.nih.gov/>

**For more information on the NIDA SBIR and STTR programs:**

<https://nida.nih.gov/funding/small-business-innovation-research-sbir-technology-transfer-sttr-programs>

### **Budget Guidance**

Award budgets and project periods are listed in the Section II Award Information of the Omnibus/Parent Notices of Funding Opportunities for SBIR and STTR. Total award budgets include direct costs, indirect costs, and fees and are capped not to exceed the total award amounts listed.

NIDA also sets its budget limits for specific research topics that received a waiver from the U.S. Small Business Administration to exceed the hard budget caps. The current list of approved NIDA topics can be found in the [SBA-Approved Waiver Topics](#). NIDA budget limit for Phase I on SBA-approved waiver topics is \$400,000 in total costs and a project period of up to 1 year. NIDA budget limit for Phase II on SBA-approved waiver topics is \$3,000,000 in total costs and a project period of up to 3 years.

In all cases, applicants should propose a budget and a project duration period that are reasonable and appropriate for the completion of the research project. Applicants are strongly encouraged to contact NIDA program officials early in the application process to receive assistance regarding the program.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIDA does not participate in the CRP program. NIDA will not accept Phase IIB applications through the Omnibus or specific program announcements.

### **Contact Information**

**Prior to Submission:** Applicants are strongly encouraged to request a technical assistance meeting with NIDA SBIR/STTR staff prior to submitting any application. To schedule a meeting, please email:

Ernestine Lentou  
Program Specialist  
NIDA Office of Translational Initiatives and Program Innovations  
[NIDASBIR@mail.nih.gov](mailto:NIDASBIR@mail.nih.gov)

**For additional information on research topics, please contact a Program Officer with the relevant area of expertise:**

Leonardo Angelone, PhD  
Program Officer  
Email: [leonardo.angelone@nih.gov](mailto:leonardo.angelone@nih.gov)

*Areas of expertise: FDA-regulated therapeutic and diagnostic devices for substance use and addiction.*

Morris Flood, DHSc  
Program Officer  
Email: [morris.flood@nih.gov](mailto:morris.flood@nih.gov)

*Areas of expertise: Consumer products and approaches that address the health-related social needs that impact substance use and addiction; and digital health technology translation to commercial substance use and addiction products that address the overall social determinants of health.*

Stacie Gutowski, PhD

Program Officer Email: [stacie.gutowski@nih.gov](mailto:stacie.gutowski@nih.gov)

*Areas of expertise: FDA-regulated therapeutic and diagnostic devices for substance use and drug addiction, including neuromodulation.*

Saravanan Karuppagounder, PhD

Program Officer

Email: [saravanan.karuppagounder@nih.gov](mailto:saravanan.karuppagounder@nih.gov)

*Areas of expertise: Therapeutics for Stimulant Use Disorders and Marijuana or Cannabis Use Disorder, Biomarker Development and Validation.*

Yordan Kostov, PhD

Program Officer

Email: [yordan.kostov@nih.gov](mailto:yordan.kostov@nih.gov)

*Areas of expertise: FDA-regulated monitoring and diagnostic devices for substance use and addiction, including target-agnostic detection.*

Tam Nguyen, PhD

Program Officer

Email: [tam.nguyen@nih.gov](mailto:tam.nguyen@nih.gov)

*Areas of expertise: Pharmacotherapeutics for opioid use disorder, overdose reversal, and smoking cessation.*

Boris Sabirzhanov, PhD

Program Officer

Email: [boris.sabirzhanov@nih.gov](mailto:boris.sabirzhanov@nih.gov)

*Areas of expertise: Helping to End Addiction Long-term (HEAL) initiative.*



# NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD)

<http://www.nidcd.nih.gov>

For more information on the NIDCD SBIR and STTR programs:

<https://www.nidcd.nih.gov/funding/types/small-business-grants>

## **Budget Guidance**

Total funding (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting the application. The Small Business Administration has allowed NIDCD to make awards that exceed these amounts for the areas noted in the [SBA-Approved Waiver Topics](#). For topics listed in the [SBA-Approved Waiver Topics](#), the NIDCD generally will not fund Phase I applications greater than \$385,000 total costs or Phase II applications greater than \$3,000,000 total costs. All applications must contain sufficient detail to justify the requested budget, and NIDCD may decrease the length of an award and/or the budget as recommended by a review committee or administrative review.

## **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIDCD does not accept applications for Phase IIB competing renewal awards.

NIDCD participates in the SBIR Commercialization Readiness Pilot program.

## **Contact Information**

For administrative and business management questions, contact:

Ms. Samantha Tempchin  
Grants Management Officer  
National Institute on Deafness and Other Communication  
Disorders 301-435-0713, Fax: 301-451-5370  
Email: [tempchins@nidcd.nih.gov](mailto:tempchins@nidcd.nih.gov)

For additional information on the following research topics, contact:

### **Hearing and Balance, BCI Communication Prostheses, Taste and Smell Programs**

Roger L. Miller, Ph.D.  
National Institute on Deafness and Other Communication  
Disorders 301-402-3458  
Email: [roger.miller@nih.gov](mailto:roger.miller@nih.gov)

### **Language Program**

Holly L. Storkel, Ph.D.  
National Institute on Deafness and Other Communication  
Disorders 301-451-6842, Fax: 301-402-0390  
Email: [holly.storkel@nih.gov](mailto:holly.storkel@nih.gov)

### **Voice & Speech Program**

Lisa M. Kopf, Ph.D.  
National Institute on Deafness and Other Communication  
Disorders 240-678-2544, Fax: 301-402-0390  
Email: [lisa.kopf@nih.gov](mailto:lisa.kopf@nih.gov)

## **NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR)**

<https://www.nidcr.nih.gov/>

**For more information on the NIDCR SBIR and STTR programs:**

<https://sbir.nih.gov/nidcr>

### **Budget Guidance**

Total funding (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting the application. The Small Business Administration has allowed NIDCD to make awards that exceed these amounts for the areas noted in the [SBA-Approved Waiver Topics](#). All applications must contain sufficient detail to justify the requested budget, and NIDCR may decrease the length of an award and/or the budget as recommended by a review committee or administrative review.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIDCR does not accept Phase IIB renewal applications. NIDCR participates in the CRP program but does not support clinical trials through the CRP program.

### **Contact Information**

For additional information on research topics, contact:

Orlando Lopez, Ph.D.

Dental and Craniofacial Small Business Coordinator

Division of Extramural Research

National Institute of Dental and Craniofacial Research

6701 Democracy Blvd., Rm. 612

Bethesda, MD 20892-4878

(301) 402-4243

Email: [orlando.lopez@nih.gov](mailto:orlando.lopez@nih.gov)

For administrative and business management questions,

contact: Gabriel Hidalgo, MBA

Acting Chief Grants Management Officer

National Institute of Dental and Craniofacial Research

6701 Democracy Blvd., Rm. 656

Bethesda, MD 20892-4878

(301) 827-4630

Email: [gabriel.hidalgo@nih.gov](mailto:gabriel.hidalgo@nih.gov)

## NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK)

<https://www.niddk.nih.gov/>

For more information on the NIDDK SBIR and STTR programs:

[https://seed.nih.gov/NIDDK\\_small\\_business\\_programs](https://seed.nih.gov/NIDDK_small_business_programs)

### **Budget Guidance**

For budgetary, administrative, or programmatic reasons, the NIDDK may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found in the “Award Budget” section of the current Omnibus Solicitations. With appropriate justification from the applicant, the NIDDK may consider budgets that exceed these amounts to support research that aligns with an approved waiver topic (see [SBA-Approved Waiver Topics](#)).

The NIDDK generally considers:

- Phase I budgets up to \$350,000 total costs or project periods up to 2 years.
- Phase II applications up to \$2,200,000 total costs or project periods up to 3 years (Phase II budgets generally should not exceed \$1,100,000 total costs in any year).
- Phase IIB (see below) applications up to \$3,000,000 total costs or project periods up to 3 years (Phase IIB budgets generally should not exceed \$1,100,000 total costs in any year).

*Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff with a draft of their Specific Aims page before submitting an application.*

The NIDDK also participates in the SBIR/STTR Commercialization Readiness Pilot (CRP) Program. Applicants should review the Award Budget section of relevant Notices of Funding Opportunities. For Phase II awardees, especially those developing products that require clinical evaluation or approval by a Federal regulatory agency, the NIDDK strongly encourages potential applicants to apply to NIDDK’s Phase IIB program.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIDDK will accept Phase IIB SBIR/STTR Competing Renewal grant applications (only) from NIDDK-supported Phase II awardees that propose to continue the process of developing products that ultimately require 1) clinical evaluation, 2) approval by a Federal regulatory agency, and 3) continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. Such products include, but are not limited to biological products, devices, drugs, medical implants, etc. related to the mission of the NIDDK. These awards are intended to support completion of research needed for an Investigational New Drug (IND) application or Investigational Device Exemption (IDE). Applicants must provide evidence that they have consulted formally with the U.S. the Food and Drug Administration (FDA) concerning the research needed for the development of a drug, biologic or medical device and that the proposed research will address these regulatory requirements. Such evidence should include FDA correspondence from a pre-IND meeting for an IND application or a pre-IDE meeting for an IDE application, and the status of the project in a

timeline related to Federal regulatory approval processes. Applicants should describe these consultations and the outcomes in the Progress Report section of the Research Strategy and provide FDA correspondence or meeting minutes as part of Just-in-Time procedures.

Examples of research that would be considered responsive to this announcement are listed below for illustrative purposes and are not exclusive of other appropriate activities.

- Completion of studies as required by the FDA for an IND or Radioactive Drug Research Committee (RDRC) application.
- Assessment of devices with regard to performance standards related to the FDA approval process.
- Clinical studies in support of an application for clearance or approval by the FDA. See the table below and review NIDDK's Policies for Clinical Researchers (<https://www.niddk.nih.gov/research-funding/human-subjects-research/policies-clinical-researchers>) when considering an application involving human subjects.

The NIDDK also participates in the SBIR/STTR Commercialization Readiness Pilot (CRP) Program. Please review CRP NOFOs for NIDDK's participation. For Phase II awardees, especially those developing products that require clinical evaluation or approval by a Federal regulatory agency, the NIDDK strongly encourages potential applicants to apply to NIDDK's Phase IIB program.

### **Contact Information**

For additional information on research topics, contact:

#### **Diabetic Technology, Type 1 Diabetes and Endocrine Diseases**

Dr. Guillermo Arreaza-Rubín

National Institute of Diabetes and Digestive and Kidney Diseases

Phone: 301-594-4724

Email: [arreaza-rubing@niddk.nih.gov](mailto:arreaza-rubing@niddk.nih.gov)

#### **Diabetic Wound Healing and Type 2 Diabetes**

Dr. Yan Li

National Institute of Diabetes and Digestive and Kidney

Diseases Phone: 301-435-3721

Email: [yan.li5@nih.gov](mailto:yan.li5@nih.gov)

#### **Neuromodulation, Diabetic Neuropathy, and Type 2 Diabetes Drug Discovery**

Dr. Bradley M. Cooke

National Institute of Diabetes and Digestive and Kidney

Diseases Phone: 301-480-9896

Email: [brad.cooke@nih.gov](mailto:brad.cooke@nih.gov)

#### **Gastrointestinal, Obesity, and Nutrition Disorders and Diseases**

Dr. Robert Lunsford

National Institute of Diabetes and Digestive and Kidney

Diseases Phone: 301-402-1397

Email: [robert.lunsford@nih.gov](mailto:robert.lunsford@nih.gov)

#### **Liver, Pancreatic, and Neurobiological Disorders and Diseases**

Ms. Christine Densmore

National Institute of Diabetes and Digestive and Kidney

Diseases Phone: 301-402-8714

Email: [christine.densmorec@nih.gov](mailto:christine.densmorec@nih.gov)

**Kidney, Urologic and Hematologic Diseases**

Dr. Daniel R. Gossett

National Institute of Diabetes and Digestive and Kidney

Diseases Phone: 301-594-7723

Email: [daniel.gossett@nih.gov](mailto:daniel.gossett@nih.gov)

For administrative and business management questions, contact:

Ms. Christina Coriz

National Institute of Diabetes and Digestive and Kidney Diseases

Phone: 301-594-8848

Email: [christina.coriz@nih.gov](mailto:christina.coriz@nih.gov)

## NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS)

<http://www.niehs.nih.gov>

For more information on the NIEHS SBIR and STTR programs:

<https://www.niehs.nih.gov/funding/grants/mechanisms/sbir>

### **Budget Guidance**

For all NIEHS research interest topic areas other than Hazardous Substances Remediation and Site Characterization SBIR Program included in this PHS 2024 Omnibus SBIR/STTR Solicitation, NIEHS will accept SBIR/STTR application total funding support (direct costs, indirect costs, and fee) requests up to \$306,872 for Phase I and \$2,045,816 for Phase II. NIEHS will not fund applications at budget levels exceeding these hard cap budget guidelines, except through specific RFAs. For budgetary, administrative, or programmatic reasons, NIEHS may decide not to fund an application or may decrease the length of an award and/or the budget. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project, and the budget request must be well justified. The Hazardous Substances Remediation and Site Characterization SBIR Program has different limits on budget requests and the applicants are strongly encouraged to stay within total allowed funding support request (direct costs, indirect costs, and fees) of \$183,460 for Phase I and \$1,223,064 for Phase II awards.

NIEHS will consider well justified Technical and Business Assistance (TABAs) costs up to the limits specified on the [NIH SEED website](#). These costs can be requested in addition to the Phase I and II limits indicated above.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIEHS does not intend to support any new Phase II B grants in this funding period. NIEHS currently participates in [PAR-23-219](#): SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed).

### **Contact Information**

For additional information on research topics, contact:

Dr. Daniel Shaughnessy  
National Institute of Environmental Health Sciences  
Division of Extramural Research and Training  
POB 12233 (K3-12)  
Research Triangle Park, NC 27709  
(984) 287-3321  
Email: [shaughn1@niehs.nih.gov](mailto:shaughn1@niehs.nih.gov)

Dr. Lingamanaidu V. Ravichandran  
National Institute of Environmental Health Sciences  
Division of Extramural Research and Training  
POB 12233 (K3-05)  
Research Triangle Park, NC 27709  
(984)-287-3309  
Email: [lingamanaidu.ravichandran@niehs.nih.gov](mailto:lingamanaidu.ravichandran@niehs.nih.gov)

For information on the NIEHS Superfund Research Program - Hazardous Substances Remediation and Site Characterization SBIR Program, contact:

Dr. Heather Henry  
National Institute of Environmental Health Sciences  
Division of Extramural Research and Training  
POB 12233 (K3-12)  
Research Triangle Park, NC 27709  
(984) 287-3268  
Email: [henryh@niehs.nih.gov](mailto:henryh@niehs.nih.gov)

For administrative and business management questions contact:

Mr. Clark A. Phillips  
National Institute of Environmental Health Sciences  
Division of Extramural Research and Training  
Grants Management Branch  
(984) 287-4037  
Email: [clark.phillips@nih.gov](mailto:clark.phillips@nih.gov)

## NATIONAL EYE INSTITUTE (NEI)

<http://www.nei.nih.gov>

**For more information on the NEI SBIR and STTR programs:**

<https://www.nei.nih.gov/grants-and-training/funding-opportunities/programs-and-research-priorities/small-business>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, NEI may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application. For topics listed in [SBA-Approved Waiver Topics](#), NEI does not generally fund Phase I applications greater than \$300,000 total costs or project periods greater than 2 years; or Phase II applications greater than \$2,000,000 total costs or project periods greater than 3 years. Applicants are strongly encouraged to contact program officials prior to submitting any application in excess of the hard caps listed above and early in the application planning process.

### **Phase IIB Competing Renewal Awards and Commercial Readiness Pilot (CRP)**

The NEI will only accept SBIR Phase IIB Competing Renewal grant applications from Phase II SBIR awardees to continue the process of developing technologies that ultimately require federal regulatory approval or require extraordinary time and effort in the Research and Development phase. Such technologies include, but are not limited to, pharmacologic agents, biological products, and devices. These technologies should be clearly related to the mission of the NEI. This renewal grant should allow small businesses to reach a stage in the project where interest and investment by third parties is more likely. The NEI expects that the Phase IIB grant will accelerate the transition of SBIR Phase II projects to the commercialization stage. The NEI encourages applicants to establish business relationships with third-party investors and/or strategic partners who can provide substantial financing to help accelerate the commercialization of promising new products and technologies that were initiated with SBIR funding.

The Competing Renewal application must be a logical extension of a previously completed Phase II (R44) SBIR grant. NEI grantees seeking SBIR Phase IIB Competing Renewal funding must submit an application within a period no later than the first six receipt dates following expiration of the previous Phase II budget period. Cumulative budgets should not exceed \$1,800,000 total costs, or time periods beyond three (3) years.

Although matching funds are not required, the NEI strongly encourages that applicants obtain significant private investment. Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds.

Applicants are strongly encouraged to contact the NEI Program Officer, Dr. Paek Lee (contact information provided below) prior to submitting any application in excess of the hard caps listed above and early in the application planning process.



## **Contact Information**

For more information on research topics, contact:

### **Paek Lee, Ph.D.**

Program Director, Small Business  
SBIR/STTR Division of Extramural Science Programs  
National Eye Institute  
6700B Rockledge Drive  
Bethesda, MD 20817  
301-435-8164  
Email: [paek.lee@nih.gov](mailto:paek.lee@nih.gov)

### **Tony D. Gover, Ph.D.**

Program Director, Small Business SBIR/STTR (Anterior Segment)  
Division of Extramural Science  
Programs National Eye  
Institute 6700B Rockledge  
Drive Bethesda, MD 20817  
301-529-7370  
Email: [tony.gover@nih.gov](mailto:tony.gover@nih.gov)

For administrative and business management questions, contact:

### **Ms. Karen Robinson Smith**

Chief Grants Management Officer  
Grants Management Branch  
Division of Extramural Activities  
National Eye Institute, NIH, DHHS  
6700B Rockledge Drive, Suite 3400  
Bethesda, MD 20892  
301-451-2020, Fax: 301-496-9997  
Email: [kyr@nei.nih.gov](mailto:kyr@nei.nih.gov)

## NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS)

<http://www.nigms.nih.gov>

**For more information on the NIGMS SBIR and STTR programs:**

<https://www.nigms.nih.gov/grants-and-funding/research-funding/small-business-research>

### **Budget Guidance**

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). NIGMS will not accept applications with budget requests exceeding this hard cap with the exception of projects that fit within the [SBA-Approved Waiver Topics](#) list for awards over the statutory budget limitations. NIGMS sets its own budget limits for the specific research topics that are granted a waiver to exceed the U.S. Small Business Administration hard budget caps. The NIGMS budget limit for a Phase I project on an approved topic is \$350,000 in total costs with a project period up to 1 year. The budget limit for a Phase II project on an approved topic is \$2,500,000 in total costs for a project period up to 3 years. If considering a project with a budget exceeding the hard cap, applicants are strongly encouraged to contact NIGMS program officials prior to submission, and preferably in the early stages of application preparation. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIGMS will accept Phase IIB SBIR-only Competing Renewal grant applications to continue the process of developing products that ultimately require 1) clinical evaluation, 2) approval by a Federal regulatory agency, or 3) continuing refinements that include but are not limited to cost reduction, testing for performance, safety, reliability and/or durability, and meeting or establishing standards, particularly for basic or clinical research instrumentation or durable medical equipment (DME) designs. This renewal grant should enhance the likelihood that small business will attract interest and investment by third parties. Such products include, but are not limited to research equipment, biological products, devices, drugs, medical implants, etc. within the mission of the NIGMS. Budgets for this Phase IIB Competing Renewal opportunity must follow the guidelines for Phase II applications (described above). For awards that are intended to support completion of research needed to obtain an Investigational New Drug application (IND) or Investigational Device Exemption (IDE), applicants must provide evidence that they have consulted formally with the FDA concerning the research needed for the development of a drug, biologic or medical device and that the proposed research will address these regulatory requirements.

Such evidence should include FDA correspondence from a pre-IND meeting for an IND application or a pre-IDE meeting for an IDE application, and the status of the project in a timeline related to Federal regulatory approval processes. Applicants should describe these consultations and the outcomes in the Progress Report section of the Research Strategy and provide FDA correspondence or meeting minutes as part of Just-in-Time procedures.

Prospective applicants considering a Phase IIB Competing Renewal application are strongly encouraged to contact either the Program person of record for the Phase II award or NIGMS contacts listed at the end of this NIGMS topics announcement.

To assist NIGMS in planning for Phase IIB applications, it is helpful for prospective applicants to submit to the NIGMS Small Business Strategy Coordinator (listed below) a letter of intent that includes the following information:

- Descriptive title of the proposed research

- Phase II grant number
- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Notice of Funding Opportunity Number

The letter is non-binding and does not enter the review process. It is anticipated that only a small number of NIGMS SBIR Phase II awards will be eligible for a Phase IIB Competing Renewal award.

### **Contact Information**

For general information on the NIGMS Small Business program, contact:

Eddie Billingslea, Ph.D., NIGMS Small Business Strategy Coordinator  
Email: [NIGMS\\_SmallBusiness@nigms.nih.gov](mailto:NIGMS_SmallBusiness@nigms.nih.gov)

For scientific questions about NIGMS-funded SBIR/STTR research, contact:

Division of Pharmacology, Physiology, and Biological Chemistry  
Pharmacological and Physiological Sciences  
Sailaja Koduri, Ph.D.  
Email: [Sailaja.Koduri@nih.gov](mailto:Sailaja.Koduri@nih.gov)

Biochemistry and Bio-related Chemistry  
Kadir Aslan, Ph.D.  
Email: [kadir.aslan@nih.gov](mailto:kadir.aslan@nih.gov)

Division of Biophysics, Biomedical Technology, and Computational Biosciences  
Ashley Barnes, Ph.D.  
Email: [ashley.barnes@nih.gov](mailto:ashley.barnes@nih.gov)

Division for Research Capacity Building  
Krishan Arora, Ph.D.  
301-435-0763  
Email: [arorak@nigms.nih.gov](mailto:arorak@nigms.nih.gov)

Research and Development in Science Education  
Tony Beck, Ph.D.  
301-480-4623  
Email: [beckL@mail.nih.gov](mailto:beckL@mail.nih.gov)

For administrative and business management questions, contact:

Administrative and Business Management  
Mr. Brian Iglesias  
301-451-5903  
Email: [iglesiab@mail.nih.gov](mailto:iglesiab@mail.nih.gov)

Ms. Ilene Glassman  
301-594-4648  
Email: [ilene.glassman@nih.gov](mailto:ilene.glassman@nih.gov)

Ms. Alania Foster  
301-451-8255  
Email: [alania.foster@nih.gov](mailto:alania.foster@nih.gov)

## NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI)

<https://www.nhlbi.nih.gov/>

For more information on the NHLBI SBIR and STTR programs:

<http://www.nhlbi.nih.gov/research/funding/sbir>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, and fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, the NHLBI reserves the right to disapprove funding or decrease the length of an award and/or the budget recommended by a review committee. NIH has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to the NHLBI that can be found in the [SBA-Approved Waiver Topics](#). It is strongly recommended for applicants who have a project that falls under one of the SBA-Approved Waiver Topics to reference the corresponding topic in their Budget Justification document. For most projects falling under one of the SBA-approved waiver topics, the NHLBI does not fund Phase I applications greater than the current SBA-mandated budget guidelines (up to \$306,872 total costs for Phase I and up to \$2,045,816 total costs for Phase II applications). However, the NHLBI may **occasionally** fund projects above these guidelines for proposals falling under one of the approved waiver topics if **one or more** of the following criteria have been fulfilled:

1. The application involves the clinical testing of therapeutics, devices, imaging agents, biologics, diagnostics, clinical and rehabilitation tools, and/or technologies.
2. The application involves the use of a large animal model. For the purpose of this guidance, large animal model species include: swine (porcine), sheep (ovine), cattle (bovine), cat (feline), dog (canine), ferret, and nonhuman primates.

Applicants with budget requests exceeding these caps **should be prepared to negotiate their budget down** if their proposal does not fall into one of the above categories.

Furthermore, all applicants with budget questions, or considering requesting a budget greater than the set budget limitation amounts, are **strongly encouraged** to contact the NHLBI SBIR office at <http://bit.ly/ContactNHLBIsbir> before submitting an application. For more information on the NHLBI Budget Policy for SBIR/STTR grants, please refer to [NOT-HL-24-008](#).

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NHLBI only accepts Phase IIB SBIR/STTR Competing Renewal applications through specific opportunities. These opportunities can be found on the NHLBI Funding Opportunities webpage: <https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/small-business-program>. Applicants are strongly encouraged to contact Dr. Jain Krotz at [jain.krotz@nih.gov](mailto:jain.krotz@nih.gov) for additional information on Phase IIB funding opportunities.

The NHLBI welcomes the submission of Commercialization Readiness Pilot (CRP) program applications from current or past Phase II/IIB awardees. The CRP aims to facilitate the transition of previously or currently funded SBIR and STTR Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later-stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts. NHLBI will accept budgets up to \$500,000 total costs (direct costs, indirect costs, fee) across up to two years. NHLBI participates in the following CRP NOFOs below:

- SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development - Clinical Trial Not Allowed ([PAR-23-219](#))
- SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development - Clinical Trial Required ([PAR-23-220](#))

### **Contact Information**

For general questions about the NHLBI SBIR/STTR grant program, please contact:

Stephanie Davis, Ph.D.

Division of Extramural Research Activities

Phone: 1-301-496-8412

Email: [nhlbi\\_sbir@mail.nih.gov](mailto:nhlbi_sbir@mail.nih.gov)

For administrative and business management questions, please contact:

Andre Walker

Division of Extramural Research

Activities Phone: 1-301-827-8061

Email: [walkera@nhlbi.nih.gov](mailto:walkera@nhlbi.nih.gov)

### **Cardiovascular Sciences**

Rahul Thakar, Ph.D.

Division of Cardiovascular Sciences

Advanced Technologies and Surgery Branch

Phone: 301-827-8151

Email: [rahul.thakar@nih.gov](mailto:rahul.thakar@nih.gov)

### **Lung Diseases and Sleep and Circadian Biology**

Lei Xiao, M.D., Ph.D.

Division of Lung Diseases

Restrictive and Vascular Lung Diseases Branch

Phone: 301-827-7852

Email: [lei.xiao@nih.gov](mailto:lei.xiao@nih.gov)

Sidd Shenoy, Ph.D.

Division of Lung Diseases

Acute and Infectious Lung Diseases Branch

Phone: 301-827-4751

Email: [sidd.shenoy@nih.gov](mailto:sidd.shenoy@nih.gov)

For sleep-related proposals, please contact:

Shilpy Dixit, Ph.D. Division of Lung Diseases

National Center for Sleep Disorders Research

Phone: 301-402-9064

Email: [shilpy.dixit@nih.gov](mailto:shilpy.dixit@nih.gov)

### **Blood Diseases and Resources**

Ron Warren, Ph.D.

Division of Blood Diseases and Resources

Translational Blood Science and Resources Branch

Phone: 301-827-8288

Email: [ronald.warren@nih.gov](mailto:ronald.warren@nih.gov)

Ilana Goldberg, Ph.D.  
Division of Blood Diseases and Resources  
Molecular, Cellular & Systems Blood Science  
Branch Phone: 301-496-8587  
Email: [ilana.goldberg@nih.gov](mailto:ilana.goldberg@nih.gov)

**Center for Translation Research and Implementation Science**  
Karen Plevock Haase, Ph.D.  
Implementation Science Branch  
Phone: 301-435-6820  
Email: [karen.plevock@nih.gov](mailto:karen.plevock@nih.gov)

## NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI)

<http://www.genome.gov>

For more information on the NHGRI SBIR and STTR programs:

<https://www.genome.gov/research-funding/Funding-Opportunities/NHGRI-Small-Business-Program>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#), unless the application fits an SBA-approved NHGRI waiver topic. For topics listed in the [SBA-Approved Waiver Topics](#), the NHGRI generally will not fund Phase I applications to the Omnibus greater than \$400,000 total costs or Phase II applications greater than \$2,150,000 total costs (not including the costs of [technical and business assistance](#)). For budgetary, administrative, or programmatic reasons, the NHGRI may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. **Applicants with budget questions or considering requesting a budget greater than these amounts are strongly encouraged to contact program staff before submitting an application.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NHGRI does not accept applications for Phase IIB competing renewal awards through this Omnibus solicitation. NHGRI participates in the CRP program

### **Contact Information**

For more information on research topics, contact:

Ian Nova, Ph.D.

Small Business Program Co-Lead (SBIR)

Phone: 240-987-2885

Email: [ian.nova@nih.gov](mailto:ian.nova@nih.gov)

Renee Rider, M.S., J.D., LCGC

Small Business Program Co-Lead (STTR)

Phone: 301-443-4336

Email: [renee.rider@nih.gov](mailto:renee.rider@nih.gov)

## NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH)

<http://www.nimh.nih.gov>

For more information on the NIMH SBIR and STTR programs:

<https://www.nimh.nih.gov/funding/sbir>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). NIH has received a waiver from the SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to the NIMH that can be found in the [SBA-Approved Waiver Topics](#). Please note, for budgetary, administrative, or programmatic reasons, the NIMH may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

**Applicants with budget questions or considering requesting a budget greater than the SBA defined amounts are strongly encouraged to contact program staff before submitting an application.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

The NIMH will accept Phase IIB SBIR/STTR Competing Renewal grant applications in two categories: 1) to continue research and development of technologies that ultimately require federal regulatory approval, and 2) to continue research and development of complex instrumentation, clinical research tools, or behavioral/digital health interventions and treatments.

Technologies in the former category (those that ultimately require federal regulatory approval) include but are not limited to pharmacologic agents and drugs, biological products, medical devices, vaccines, etc. related to the mission of the NIMH. Phase IIB SBIR/STTR Competing Renewal grants for such technologies should allow small businesses to move research and development to a stage where interest and investment by third parties is more likely.

Companies that are developing technologies that do not focus on drug development, but that require federal regulatory approval prior to commercialization, may be eligible to submit a Phase IIB Competing Renewal application.

For both technology areas, Phase IIB applications may be submitted through the Omnibus SBIR/STTR Notice of Funding Opportunity. Generally, for this opportunity, budget limits of \$3 million total costs and time periods up to 3 years may be requested. These budget allowances have been approved by the SBA through a waiver. For budgets higher than \$3 million, contact NIMH program staff prior to submitting the application.

The following examples would make appropriate topics for proposed NIMH SBIR/STTR Phase IIB Competing Renewal projects. These are meant for illustrative purposes only and are not exclusive of other appropriate activities:

- Preclinical studies, including pharmacology and toxicology, beyond those conducted under the Phase I (R43/R41) and initial Phase II (R44/R42) grants. Some *in vivo* or *in vitro* studies would be expected to have been carried out in Phase I or the initial Phase II grant.
- Completion of studies as required by the Food and Drug Administration (FDA) for Investigational New Drug (IND) or Radioactive Drug Research Committee (RDRC) application.
- Studies in normal healthy volunteers to determine a drug's safety profile, metabolism, etc.
- Assessment of devices with regard to performance standards related to the FDA approval process.
- Safety and effectiveness studies of novel medical devices.
- Evaluation of novel imaging approaches for diagnostic purposes.



- Clinical studies in support of Pre-Market Approval for biomarkers/medical devices by the FDA.

Although technologies in the latter category listed above (complex instrumentation, clinical research tools, or behavioral interventions/treatments) may not require federal regulatory approval, extraordinary time and effort is needed for their research and development. Therefore, NIMH supports Phase IIB Competing Renewal awards of existing Phase II grants for such technologies. The Phase IIB Competing Renewal award for these would provide up to an additional three years of support at total cost funding levels of up to \$3 million (generally) for the project. These budget allowances have been approved by the SBA through a waiver.

Please contact the Program Director in the appropriate Division or Dr. Margaret Grabb (listed below) before beginning the process of putting an application together. In addition, prospective applicants are encouraged to submit to the program contact a letter of intent that includes the following information:

- Descriptive title of the proposed research
- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Notice of Funding Opportunity (e.g., [PA-19-273](#)).

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIH staff to estimate the potential review workload and plan the review. It is expected that only a portion of NIMH SBIR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.

### **Contact Information**

Margaret Grabb, Ph.D. (general questions about the NIMH SBIR program, Phase IIB program, DNBBS, DTR divisional interests)  
National Institute of Mental Health  
6001 Executive Boulevard, Room 7133  
Rockville, MD 20852 Telephone: 301-443-3563  
Email: [mgrabb@mail.nih.gov](mailto:mgrabb@mail.nih.gov)

Adam Haim, Ph.D. (DSIR divisional interests)  
Division of Services and Intervention Research  
6001 Executive Boulevard  
Room 7273  
Rockville, MD 20852 Telephone: 301-445-3593  
Email: [haima@mail.nih.gov](mailto:haima@mail.nih.gov)

Maggie Sweeney, Ph.D. (DSIR divisional interests; send initial inquiries to Dr. Adam Haim above)  
Division of Services and Intervention Research  
6001 Executive Boulevard  
Telephone: 301-480-1582  
Email: [maggie.sweeney@nih.gov](mailto:maggie.sweeney@nih.gov)

Dr. Vasudev R Rao M.B.B.S, M.S. (DAR divisional interests)  
Division of AIDS Research  
5601 Fishers Ln  
Rockville MD 20852  
Telephone: 240-669-5609  
Email: [vasudev.rao@nih.gov](mailto:vasudev.rao@nih.gov)

Paige Anderson, M.S. (preclinical assay development)  
6001 Executive Boulevard, Room 7120.3  
Bethesda, MD 20892-9645  
Rockville, MD 20852 (for express/courier  
service) Telephone: 301-827-6550  
Email: [paige.anderson@nih.gov](mailto:paige.anderson@nih.gov)

## NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES (NIMHD)

<http://www.nimhd.nih.gov>

For more information on the NIMHD SBIR and STTR programs:

<https://www.nimhd.nih.gov/programs/extramural/sbir-sttr.html>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, the NIMHD may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. NIH has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to the NIMHD that can be found in the [SBA-Approved Waiver Topics](#). **Applicants with budget questions or considering requesting a budget greater than these amounts are strongly encouraged to contact program staff before submitting an application.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NIMHD welcomes Phase IIB Competing Renewal Applications for Phase II grants and contracts via the Omnibus Solicitation for SBIR or STTR Grant Applications, and as indicated by other NIMHD Notices of Funding Opportunities (NOFOs). Standard NIMHD Phase II funding policy applies unless otherwise stated in the NOFO. Non-NIMHD Phase II awardees must contact NIMHD prior to submission to confirm programmatic interest.

### **Contact Information**

For additional information on research topics, contact:

LCDR Michael Banyas, USPHS, M.P.A, M.A, Program Manager  
Division of Community Health and Population Science

National Institute on Minority Health and Health Disparities,

NIH Email: [michael.banyas@nih.gov](mailto:michael.banyas@nih.gov)

Phone: 301-827-7478

# NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS)

<http://www.ninds.nih.gov>

For more information on the NINDS SBIR and STTR programs:

<https://www.ninds.nih.gov/funding/ninds-small-business-program>

## **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#), unless the application fits an SBA-approved waiver topic. For topics listed in the [SBA-Approved Waiver Topics](#), NINDS generally will not fund Phase I applications to the Omnibus greater than \$700,000 total costs, with no more than \$500,000 total cost in an year or project periods greater than 2 years; or Phase II applications greater than \$3,000,000 total costs, with no more than \$1,500,000 or project periods greater than 3 years. For budgetary, administrative, or programmatic reasons, NINDS may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Information about the NINDS budget guidelines can be found on the NINDS SBIR webpage <https://www.ninds.nih.gov/funding/ninds-small-business-program/submitting-small-business-application>.

For all other funding opportunities, applications should follow the guidelines in the Award Budget section of those announcements carefully.

All applicants are strongly encouraged to contact program staff before submitting an application.

## **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NINDS only accepts Phase IIB SBIR/STTR Competing Renewal applications through specific opportunities that focus on the commercialization of SBIR and STTR developed technologies. These opportunities can be found on the NINDS Funding Opportunities webpage: <https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities>. Contact [ninds\\_sbir@ninds.nih.gov](mailto:ninds_sbir@ninds.nih.gov) for additional information.

## **Contact Information**

### **Scientific/Research Contact**

Emily Caporello, Ph.D.  
Director, NINDS Small Business Program  
Phone: 301-496-1779  
Email: [emily.caporello@nih.gov](mailto:emily.caporello@nih.gov)  
Program-wide Email: [ninds\\_sbir@ninds.nih.gov](mailto:ninds_sbir@ninds.nih.gov)

### **Financial/Grants Management Contact:**

Chief Grants Management Officer  
National Institute of Neurological Disorders and Stroke (NINDS)  
Email: [ChiefGrantsManagementOfficer@ninds.nih.gov](mailto:ChiefGrantsManagementOfficer@ninds.nih.gov)

## NATIONAL INSTITUTE OF NURSING RESEARCH (NINR)

<http://www.ninr.nih.gov>

**For more information on the NINR SBIR and STTR programs:**

<https://www.ninr.nih.gov/funding/small-business-funding>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SBIR website](#). For budgetary, administrative, or programmatic reasons, NINR may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. NIH has received a waiver from the SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to NINR that can be found in the [SBA-Approved Waiver Topics](#). NINR will generally not fund:

- Phase I applications to the Omnibus greater than \$385,000 total costs or project periods greater than 2 years, or
- Phase II applications greater than \$2,500,000 total costs or project periods greater than 3 years.

Applicants that are considering requesting a budget greater than these amounts are strongly encouraged to contact program staff before submitting an application.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NINR does not accept Phase IIB applications.

NINR does not participate in the Commercialization Readiness Pilot (CRP) Program.

### **Contact Information**

For additional information please contact:

Dr. Karen Kehl

Director, Small Business Innovation Research Program

National Institute of Nursing Research (NINR)

Division of Extramural Science Program (DESP) 6701

Democracy Blvd, Room 727

Bethesda, MD 20892-4870

Office: (301) 594-8010

Email: [karen.kehl@nih.gov](mailto:karen.kehl@nih.gov)

## NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)

<https://ncats.nih.gov>

For additional information on the NCATS SBIR and STTR programs:

<http://ncats.nih.gov/smallbusiness>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, NCATS may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

For certain topical areas, there is an [SBA-Approved Waiver Topics](#) list for which the NCATS generally will not fund:

- Phase I applications greater than \$350,000 total costs or project periods greater than 2 years
- Phase II applications greater than \$2,150,000 total costs or project periods greater than 3 years

Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

Occasionally, NCATS may accept Phase IIB SBIR Competing Renewal grant applications of NCATS supported Phase II awards to continue research and development of products that have a potential to address bottlenecks in the translational process, and where additional time and effort is needed to reach a stage where interest and investment by third parties would be likely. Such products are expected to have broad applicability and be consistent with the mission of NCATS. Applicants are strongly encouraged to speak to NCATS Program staff prior to submitting their Phase IIB application. Budgets for Phase IIB grant applications must be approved by NCATS Program staff prior to submission.

### **Contact Information**

For additional information on research topics, please contact:

Krishna 'Balki' Balakrishnan, PhD, MBA

NCATS SBIR/STTR Acting Program Director

National Center for Advancing Translational Sciences, NIH

Phone: 301-827-7149

Email: [NCATS-SBIRSTTR@mail.nih.gov](mailto:NCATS-SBIRSTTR@mail.nih.gov)

Meena U. Rajagopal, PhD

NCATS SBIR/STTR Program Officer

National Center for Advancing Translational Sciences, NIH

Phone: 301-827-1921

Email: [NCATS-SBIRSTTR@mail.nih.gov](mailto:NCATS-SBIRSTTR@mail.nih.gov)

Mayra A. Alvarez Lopez, MS

NCATS SBIR/STTR Program Analyst

National Center for Advancing Translational

Sciences, NIH Phone: 301-827-7146

Email: [NCATS-SBIRSTTR@mail.nih.gov](mailto:NCATS-SBIRSTTR@mail.nih.gov)

For Administrative, business management and grants policy questions, please contact:  
Ms. Imoni Williams  
Grants Management Specialist, SBIR/STTR Project Liaison  
Phone: 301-435-2939  
E-mail: [imoni.williams@nih.gov](mailto:imoni.williams@nih.gov)

## NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH)

<http://nccih.nih.gov>

For additional information on the NCCIH SBIR and STTR programs:

<https://www.nccih.nih.gov/grants/sbir-sttr>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the Small Business Association (SBA), which can be found on the [NIH SEED website](#). NCCIH policy on grant duration is described in [NOT-AT-20-017](#).

There is an [SBA-Approved Waiver Topics](#) list, for which NCCIH generally will not fund:

- Phase I applications greater than \$325,000 total costs per year or project periods greater than 2 years.
- Phase II applications greater than \$2,000,000 total costs for the duration of the project or project periods greater than 3 years.

Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NCCIH does not accept applications for Phase IIB.

### **Contact Information**

For additional information on research topics, please contact:

#### **Emrin Horgusluoglu, PhD**

Program Director, Division of Extramural Research  
National Center for Complementary and Integrative Health (NCCIH)  
6707 Democracy Boulevard, Suite 401  
Telephone: 240-383-5302  
Email: [emrin.horgusluoglu-moloch@nih.gov](mailto:emrin.horgusluoglu-moloch@nih.gov)



## NATIONAL LIBRARY OF MEDICINE (NLM)

<http://www.nlm.nih.gov>

**For more information on the NLM SBIR and STTR programs:**

<https://www.nlm.nih.gov/ep/grantsbir.html>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, the NLM may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. NIH has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to the NLM that can be found in the [SBA-Approved Waiver Topics](#). **Applicants with budget questions or considering requesting a budget greater than these amounts are strongly encouraged to contact program staff before submitting an application.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

NLM does not accept Phase IIB applications and does not participate in the CRP program.

### **Contact Information**

For additional information on research topics, contact:

Dr. Rebecca Moen  
Program Officer  
Division of Extramural Programs National Library of Medicine  
301-594-7593  
Email: [rebecca.moen@nih.gov](mailto:rebecca.moen@nih.gov)

For administrative and business management questions, contact:

Ms. Samantha Tempchin  
Grants Management Officer  
Extramural Programs Division National  
Library of Medicine  
301-496-4222, Fax: 301-402-0421  
Email: [samantha.tempchin@nih.gov](mailto:samantha.tempchin@nih.gov)

## DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI), OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP)

<https://orip.nih.gov>

For more information on the ORIP SBIR and STTR programs:

<https://orip.nih.gov/funding/small-business>

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed the amounts defined by the SBA, which can be found on the [NIH SEED website](#). For budgetary, administrative, or programmatic reasons, ORIP may not fund an application, may decrease the length of an award, and/or the budget recommended by a review committee. NIH has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations set by the SBA for specific topics relevant to ORIP that can be found in the [SBA-Approved Waiver Topics](#). **Applicants who have budget questions or are considering requesting a budget greater than these amounts are strongly encouraged to contact program staff before submitting an application.**

### **Phase IIB Competing Renewal Awards and Commercialization Readiness Pilot (CRP)**

ORIP will only accept Phase IIB SBIR Competing Renewal grant applications of ORIP-supported Phase II awards to continue research and development of methods, technologies, tools, and devices for basic or translational research where extraordinary time and effort are needed for completion of these projects. The Phase IIB Competing Renewal award is intended to allow small businesses the opportunity to reach a stage where interest and investment by third parties would be more likely. Such products are expected to have broad applicability, consistent with the mission of ORIP. Budgets that do not exceed \$1M per year in total costs (for up to 2 years), may be requested for this Phase IIB Competing Renewal opportunity; however, it is expected that, in most cases, the requested budget would not exceed the final year budget of the applicant's previous Phase II award. This opportunity is available for the SBIR program only.

Please contact your Program Officer before beginning the process of preparing a Phase IIB Competing Renewal application. In addition, prospective applicants are strongly encouraged to submit to the Program Contact (listed after each section) a letter of intent by email that includes the following information:

- Descriptive title of the proposed research
- Name, address, and telephone number of the Principal Investigator
- Names of other Key Personnel
- Participating organizations
- Notice of Funding Opportunity Number (e.g., PA-22-XXX)

A letter of intent is not required, is not binding, and does not enter into the review of a subsequent application. It is expected that only a few of ORIP SBIR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.

ORIP does not participate in the Commercialization Readiness Pilot (CRP) program at this time.

### **Contact Information**

For additional information on DCM research topics, contact:

Miguel Contreras, Ph.D.

Division of Comparative Medicine, Office of Research Infrastructure Programs,  
Division of Program Coordination, Planning, and Strategic Initiatives,  
Office of the Director

Phone: 301-451-7845

Email: [miguel.contreras@nih.gov](mailto:miguel.contreras@nih.gov)

For additional information on DCI research topics, contact:

Xiang-Ning Li, Ph.D.

Director

Division of Construction and Instruments, Office of Research Infrastructure Programs,  
Division of Program Coordination, Planning, and Strategic Initiatives  
Office of the Director

Phone: 301-435-0766

Email: [xiang-ning.li@nih.gov](mailto:xiang-ning.li@nih.gov)

For administrative and business management questions, contact:

Ms. Donna James

Grants Management Specialist,

National Heart, Lung, and Blood Institute (NHLBI),

Office of Research Infrastructure Programs (ORIP),

6705 Rockledge Drive, 202-G

Bethesda, MD 20817

Phone: 301-827-8063

Email: [donna.james@nih.gov](mailto:donna.james@nih.gov)

## **OFFICE OF RESEARCH ON WOMEN'S HEALTH (ORWH)**

<https://orwh.od.nih.gov/>

### **Budget Guidance**

ORWH does not award grants but co-funds women's health-related applications that have received an award from one of the participating NIH Institutes and Centers (ICs) listed in the announcement. Budgets should be discussed with Institute or Center program staff, not ORWH.

### **Contact Information**

For additional information on ORWH priorities, please contact:

Elizabeth Barr, Ph.D.  
ORWH Associate Director for Interdisciplinary Research  
Office of Research on Women's Health, NIH  
Phone: 301-402-7895  
Email: [Elizabeth.Barr@nih.gov](mailto:Elizabeth.Barr@nih.gov)

---

## CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

CDC is the nation's leading science-based, data-driven, service organization that protects the public's health. For more than 70 years, we've put science into action to help children stay healthy so they can grow and learn; to help families, businesses, and communities fight disease and stay strong; and to protect the public's health.

### **Budget Guidance**

Total funding support (direct costs, indirect costs, fees) normally may not exceed \$306,872 for Phase I awards and \$2,045,816 for Phase II awards. These are the amounts currently defined by the U.S. Small Business Administration (SBA), which can also be found on the [CDC SBIR website](#). Applicants considering a requested budget greater than these limits are **strongly encouraged** to contact CDC program staff before applying. For budgetary, administrative, or programmatic reasons, the CDC may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. CDC has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations set by SBA for specific topics relevant to CDC that can be found in the [SBA-Approved Waiver Topics Over Statutory Budget Limitations document](#).

Before considering and/or preparing an application to the CDC SBIR program, applicants are encouraged to review the websites of CDC's participating components and to contact the SBIR program staff listed below.

### **Specific SBIR and STTR Program Information**

CDC does not accept STTR applications.

CDC does not accept Direct to Phase IIs, Fast-Track, or Phase IIB.

For additional information about CDC, please visit: <http://www.cdc.gov>.

### **Research Topics/Specific Areas of Interest**

Additional information on the awarding components (CIOs) and their research interests is available electronically on the home pages shown throughout the "Research Topics/Specific Areas of Interest" sections below.

CDC encourages investigator-initiated applications that focus on support for the prevention, detection, and response to emerging public health threats. CDC also encourages investigator-initiated applications that align with the agency's overall mission and the research areas of interest of the participating CDC components below.

### **Contact Information**

General questions about the CDC SBIR program should be directed to:  
Small Business Innovation Research Program (SBIR)  
Office of Science (OS)  
Centers for Disease Control and Prevention (CDC)  
Email: [SBIR@cdc.gov](mailto:SBIR@cdc.gov)

## **GLOBAL HEALTH CENTER (GHC)**

Please visit the GHC website at: <https://www.cdc.gov/GlobalHealth/>.  
For GHC programmatic information, contact:

Lata Kumar, MS, MPH, MBA  
Office of the Director  
Center for Global Health Center  
Centers for Disease Control and Prevention (CDC) Mail Stop H21-9  
1600 Clifton Road NE Atlanta, GA 30329  
Phone: (404) 639-7618  
Email: [LKumar@cdc.gov](mailto:LKumar@cdc.gov)

For grants specific, administrative information, contact:

Angie Willard, Team Lead  
Office of Grant Services  
Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop TV-2  
2939 Flowers Road NE  
Atlanta, GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD)**

Please visit the NCBDDD website at: <http://www.cdc.gov/ncbddd/index.html>.  
For NCBDDD programmatic information, contact:

Natalie Brown, MPH  
Office of the Director  
National Center for Chronic Disease Prevention and Health Promotion  
Centers for Disease Control and Prevention (CDC)  
Mail Stop S107-8  
4770 Buford Highway  
Atlanta, GA 30341  
Phone: 404-639-4601  
Email: [NBrown3@cdc.gov](mailto:NBrown3@cdc.gov)

For grants specific, administrative information, contact:

Brownie Anderson-Rana  
Office of Grant Services  
Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop K-75  
2920 Brandywine Rd.  
Atlanta, GA 30341  
Phone: 770-488-2771  
Email: [BAndersonRana@cdc.gov](mailto:BAndersonRana@cdc.gov)

## **NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP)**

Please visit the NCCDPHP web site at: <http://www.cdc.gov/chronicdisease/index.htm>.  
For NCCDPHP programmatic information, contact:

Natalie Brown, MPH  
Office of the Director  
National Center for Chronic Disease Prevention and Health Promotion  
Centers for Disease Control and Prevention (CDC)  
Mail Stop S107-8  
4770 Buford Highway  
Atlanta, GA 30341  
Phone: 404-639-4601  
Email: [NBrown3@cdc.gov](mailto:NBrown3@cdc.gov)

For grants specific, administrative information, contact:

Angie Willard, Team Lead  
Office of Grant Services Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop, T2939 Flowers Road NE Atlanta, GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL CENTER FOR EMERGING AND ZOO NOTIC INFECTIOUS DISEASES (NCEZID)**

Please visit the NCEZID website at: <http://www.cdc.gov/ncezid>.  
For NCEZID programmatic information, contact:

Amy Yang, PhD  
National Center for HIV, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention (CDC)  
Phone: 404-718-8836  
Email: [VDZ9@cdc.gov](mailto:VDZ9@cdc.gov)

For grants specific, administrative information, contact:

Angie Willard, Team Lead  
Office of Grant Services Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop TV-2  
2939 Flowers Road NE Atlanta, GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL CENTER FOR ENVIRONMENTAL HEALTH (NCEH)**

Please visit the NCEH web site at: <https://www.cdc.gov/nceh/>.

For NCEH programmatic information, contact:

Tonia Linley  
Program Specialist  
National Center for Injury Prevention and Control  
Centers for Disease Control and Prevention CDC  
Phone: 770-488-3593  
Email: [IMX9@cdc.gov](mailto:IMX9@cdc.gov) or [NCIPC\\_ERPO@cdc.gov](mailto:NCIPC_ERPO@cdc.gov)

For grants specific, administrative information, contact:

Brownie Anderson-Rana  
Office of Grant Services Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop K-75  
2920 Brandywine Rd.  
Atlanta, GA 30341  
Phone: 770-488-2771  
Email: [BAAndersonRana@cdc.gov](mailto:BAAndersonRana@cdc.gov)



## **NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP)**

Please visit the NCHHSTP website at: <http://www.cdc.gov/nchhstp/>.

For NCHHSTP programmatic information, contact:

Amy Yang, PhD  
Extramural Research Program Office  
Office of the Associate Director for Science  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention (CDC)  
Phone: 404-718-8836  
Email: [VDZ9@cdc.gov](mailto:VDZ9@cdc.gov)

For grants specific, administrative information, contact:

Angie Willard, Team Lead  
Office of Grant Services Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop TV-2  
2939 Flowers Road NE Atlanta, GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD)**

Please visit the NCIRD website at: <http://www.cdc.gov/ncird/>.

For NCIRD programmatic information, contact:

Amy Yang, PhD  
Extramural Research Program Office  
Office of the Associate Director for Science  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention (CDC)  
Phone: 404-718-8836  
Email: [VDZ9@cdc.gov](mailto:VDZ9@cdc.gov)

For grants specific, administrative information, contact:

Angie Willard, Team Lead  
Office of Grant Services Office of Financial  
Resources Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop TV-2  
2939 Flowers  
Road NE Atlanta,  
GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL (NCIPC)**

To learn more about NCIPC, please visit the NCIPC website at: <http://www.cdc.gov/injury/index.html>.  
For NCIPC programmatic information, contact:

Tonia Linley  
Program Specialist  
National Center for Injury Prevention and Control  
Centers for Disease Control and Prevention CDC  
Phone: 770-488-3593  
Email: [IMX9@cdc.gov](mailto:IMX9@cdc.gov) or [NCIPC\\_ERPO@cdc.gov](mailto:NCIPC_ERPO@cdc.gov)

For grants specific, administrative information contact:

Angie Willard, Team Lead  
Office of Grant Services  
Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC)  
Mail Stop TV-2  
2939 Flowers Road NE Atlanta, GA 30341  
Phone: 770-498-2596  
Email: [AEN4@cdc.gov](mailto:AEN4@cdc.gov)

## **NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH)**

For additional information about NIOSH, please visit their web site at:  
<http://www.cdc.gov/niosh/programs>.

NIOSH typically supports Phase I awards at the maximum allowable total cost as stated in the funding announcement. However, in most cases Phase II applications are limited to a maximum total cost of \$1M for the two-year period of performance.

Visit the NIOSH homepage for more information on NIOSH's research program areas  
<http://www.cdc.gov/niosh/homepage.html>.

For NIOSH programmatic information, contact:

Steve Dearwent, PhD  
National Institute for Occupational Safety and Health (NIOSH)  
Centers for Disease Control and Prevention  
Mail Stop V24-4  
Phone: 404-498-6382  
Email: [sdearwent@cdc.gov](mailto:sdearwent@cdc.gov)

For grants specific, administrative information, contact:

Brownie Anderson-Rana  
Office of Grant Services Office of Financial Resources  
Office of the Chief Operating Officer  
Centers for Disease Control and Prevention (CDC) Mail Stop K-75  
2920 Brandywine Rd.  
Atlanta, GA 30341  
Phone: 770-488-2771  
Email: [BAndersonRana@cdc.gov](mailto:BAndersonRana@cdc.gov)

## **FOOD AND DRUG ADMINISTRATION (FDA)**

The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get accurate, science-based information they need to use medicines and foods to improve their health.

For additional information about areas of interest to the FDA, please visit our home page at <http://www.fda.gov>.

### **Budget Guidance**

FDA will not fund:

- Phase I applications greater than \$200,000
- Phase II applications greater than \$1,500,000

### **Contact Information**

For additional information on research topics and administrative and business information, contact

Kimberly Pendleton  
Director, Division of Grants, Agreements, and Acquisition Support  
Email: [Kimberly.Pendleton@fda.hhs.gov](mailto:Kimberly.Pendleton@fda.hhs.gov)  
Food and Drug Administration  
Division of Acquisition Support and Grants